Pharmaceutical sales: approx. 70%
Biopharmaceutical sales: approx. 20%
Research and development services: approx. 10%

TOP 3 markets:

1. China: approx. 60%
2. USA: approx. 20%
3. Europe: approx. 10%

Hansoh Pharmaceutical Group Company Limited generates the majority of its revenue from the pharmaceutical industry, particularly through the sale of generics and innovative drugs. A significant portion of the revenue also comes from biopharmaceuticals, which have seen strong growth in recent years.

China remains the largest market for the company, attributed to its strong local presence and the growing demand for health products. The U.S. market is the second largest, followed by Europe, where the company has expanded its market share through strategic partnerships and expansions.

Production sites: Lianyungang, China

Hansoh Pharmaceutical Group Company Limited mainly produces its products in Lianyungang, China. This location is known for its advanced production facilities and plays a central role in the manufacturing of the company's pharmaceutical products. The strategic location in China enables Hansoh to efficiently serve both the domestic and international markets.

Focus on Research and Development: Increase in R&D budget by 20% (2024)

Expansion into international markets: Market entry into Europe and North America (2024)

Product pipeline: Introduction of three new drugs in the next two years (2025-2026)

Hansoh Pharmaceutical Group Company Limited is pursuing a growth strategy that heavily focuses on research and development. The company has significantly increased its R&D budget to develop innovative drugs and expand its product pipeline. This includes in particular the introduction of new drugs that are expected to come to market in the coming years.

In addition, Hansoh plans a geographical expansion, especially into the European and North American markets. This expansion is intended to be supported by strategic partnerships and alliances to accelerate market penetration.

The combination of increased R&D investment and international expansion aims to strengthen Hansoh's market position and ensure long-term growth.

Imported raw materials/materials: Active pharmaceutical ingredients (APIs), excipients, packaging materials

Countries of origin: India, China, Germany, USA

Hansoh Pharmaceutical Group Company Limited mainly imports active pharmaceutical ingredients (APIs) needed for the production of their medications. India and China are leading exporters of APIs and supply a large portion of these raw materials. Additionally, the company sources excipients and packaging materials necessary for the production and distribution of their products.

Germany and the USA are also important partners, especially for specialized chemical compounds and high-quality packaging solutions. These countries offer advanced technologies and quality standards crucial for pharmaceutical production.

Market share in China: 5% (2024, estimated)
R&D expenses: 15% of revenue (2024)
Patent portfolio: Over 200 patents (2024)

Hansoh Pharmaceutical Group Company Limited has a significant competitive advantage due to its strong presence in the Chinese market, where it holds an estimated market share of 5%. This is supported by continuous investments in research and development, which account for about 15% of revenue. These investments enable the company to develop and bring innovative products to the market.

The extensive patent portfolio with over 200 patents provides Hansoh with protection against imitative products and strengthens its position in the specialized medicines sector. The strategic focus on research and development, as well as the protection provided by patents, are crucial factors that help the company stand out from the competition.

Additionally, Hansoh benefits from a strong distribution structure and established partnerships that facilitate market access and increase the reach of its products. Together, these factors give Hansoh a sustainable competitive advantage in a dynamic and highly competitive market.

Institutional investor share: Approx. 45% (estimate based on 2023 data)

Insider purchases/sales: No significant transactions in the last year (2024)

The institutional investor share in Hansoh Pharmaceutical Group Company Limited is estimated to be around 45%. This indicates a strong interest from institutional investors, suggesting confidence in the company's long-term development.

In 2024, there were no significant insider transactions, indicating that the management may not expect significant changes in the company's value or that the current valuation is considered fair.

Market share of Hansoh Pharmaceutical: Estimate: 5-7% (2025)

Main competitors and their market shares:

1. China National Pharmaceutical Group (Sinopharm): 15%
2. Shanghai Pharmaceuticals Holding Co., Ltd.: 12%
3. CSPC Pharmaceutical Group Limited: 10%
4. Hengrui Medicine: 9%
5. Hansoh Pharmaceutical Group Company Limited: 5-7%
6. Fosun Pharma: 5%
7. Sino Biopharmaceutical Limited: 4%
8. Jiangsu Hengrui Medicine Co., Ltd.: 3%

Moat of Hansoh Pharmaceutical:

Hansoh Pharmaceutical has a moderate moat, mainly supported by its strong research and development capabilities and a broad product portfolio. The company continuously invests in innovative drugs, giving it a certain competitive advantage. Additionally, Hansoh has a strong presence in oncology and central nervous systems, which is considered a strategic advantage.

Compared to its competitors, especially Sinopharm and Shanghai Pharmaceuticals, which have extensive distribution networks and a larger product diversification, the moat of Hansoh is less pronounced. These companies benefit from their size and established market share, giving them a stronger competitive edge.

In summary, Hansoh Pharmaceutical has some significant advantages, but it is surpassed by some of its larger competitors in terms of market share and resources. To expand its moat, Hansoh could benefit from strategic partnerships and further diversification of its product portfolio.

Revenue growth: 10.5% (2024) Research and development ratio: 18% of revenue (2024) Market share in China: 5% in the oncology sector (2024)

Hansoh Pharmaceutical Group recorded a revenue growth of 10.5% in 2024, attributed to a strong product pipeline and successful market launches. The company continues to heavily invest in research and development, with a ratio of 18% of revenue, indicating a strategic focus on innovation and long-term growth.

The 5% market share in the oncology sector in China shows that Hansoh holds a significant position in one of the most important and fastest-growing segments of the pharmaceutical market. These factors suggest that Hansoh Pharmaceutical Group is well positioned to benefit from future growth opportunities, especially in a rapidly evolving healthcare market like China.

In summary, the strategic investments in research and development, as well as the strong market position in a key segment, indicate that Hansoh Pharmaceutical Group's stock could be an attractive investment opportunity, especially for investors interested in long-term growth.

Dividend payment: No dividend (as of 2025)

Hansoh Pharmaceutical Group Company Limited has not distributed any dividends to its shareholders so far. The company focuses on reinvesting its profits in research and development as well as expanding into new markets.

Therefore, the reliability of dividend payment is not relevant as the company currently does not pursue a dividend policy. Investors should rather focus on the growth potential and innovation capabilities of the company.